Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity

Naoko Komiya, Hiroshi Hirose, Hiroshi Kawabe, Hiroshi Itoh, Ikuo Saito

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim: Telmisartan, an angiotensin receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPARγ) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity. Methods: This study included 19 Japanese male hypertensive subjects, aged 51.2 ± 7.6 (mean ± SD) years, and body mass index 27.7 ± 4.1 kg/m2. In these subjects, 14 were naive to telmisartan treatment (40.0 ±15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit. Results: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p 0.001 for both). Serum HMW-adiponectin level increased from 2.06 2+ 0.81 to 2.40 ± 0.96 μg/mL (+ 16.4%, p = 0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n 14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p = 0.0015 for both), and serum HMW-adiponectin level increased from 2.07 ± 0.68 to 2.39 ± 0.99 μg/mL (+ 15.5%, p = 0.089). Conclusion: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalJournal of Atherosclerosis and Thrombosis
Volume16
Issue number2
Publication statusPublished - 2009

Fingerprint

Metabolome
Abdominal Obesity
Adiponectin
Molecular Weight
Molecular weight
Serum
Blood pressure
Blood Pressure
C-Reactive Protein
Therapeutics
Insulin
PPAR gamma
Angiotensin Receptor Antagonists
telmisartan
Adipocytes
Insulin Resistance
Atherosclerosis
Body Mass Index
Enzyme-Linked Immunosorbent Assay
Body Weight

Keywords

  • High-sensitivity C-reactive protein
  • Insulin resistance
  • Obesity
  • PPAR gamma

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Biochemistry, medical

Cite this

@article{421ae121be0d4a329a433289f0c64c77,
title = "Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity",
abstract = "Aim: Telmisartan, an angiotensin receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPARγ) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity. Methods: This study included 19 Japanese male hypertensive subjects, aged 51.2 ± 7.6 (mean ± SD) years, and body mass index 27.7 ± 4.1 kg/m2. In these subjects, 14 were naive to telmisartan treatment (40.0 ±15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit. Results: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p 0.001 for both). Serum HMW-adiponectin level increased from 2.06 2+ 0.81 to 2.40 ± 0.96 μg/mL (+ 16.4{\%}, p = 0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n 14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p = 0.0015 for both), and serum HMW-adiponectin level increased from 2.07 ± 0.68 to 2.39 ± 0.99 μg/mL (+ 15.5{\%}, p = 0.089). Conclusion: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.",
keywords = "High-sensitivity C-reactive protein, Insulin resistance, Obesity, PPAR gamma",
author = "Naoko Komiya and Hiroshi Hirose and Hiroshi Kawabe and Hiroshi Itoh and Ikuo Saito",
year = "2009",
language = "English",
volume = "16",
pages = "137--142",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "2",

}

TY - JOUR

T1 - Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity

AU - Komiya, Naoko

AU - Hirose, Hiroshi

AU - Kawabe, Hiroshi

AU - Itoh, Hiroshi

AU - Saito, Ikuo

PY - 2009

Y1 - 2009

N2 - Aim: Telmisartan, an angiotensin receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPARγ) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity. Methods: This study included 19 Japanese male hypertensive subjects, aged 51.2 ± 7.6 (mean ± SD) years, and body mass index 27.7 ± 4.1 kg/m2. In these subjects, 14 were naive to telmisartan treatment (40.0 ±15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit. Results: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p 0.001 for both). Serum HMW-adiponectin level increased from 2.06 2+ 0.81 to 2.40 ± 0.96 μg/mL (+ 16.4%, p = 0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n 14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p = 0.0015 for both), and serum HMW-adiponectin level increased from 2.07 ± 0.68 to 2.39 ± 0.99 μg/mL (+ 15.5%, p = 0.089). Conclusion: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.

AB - Aim: Telmisartan, an angiotensin receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPARγ) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity. Methods: This study included 19 Japanese male hypertensive subjects, aged 51.2 ± 7.6 (mean ± SD) years, and body mass index 27.7 ± 4.1 kg/m2. In these subjects, 14 were naive to telmisartan treatment (40.0 ±15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit. Results: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p 0.001 for both). Serum HMW-adiponectin level increased from 2.06 2+ 0.81 to 2.40 ± 0.96 μg/mL (+ 16.4%, p = 0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n 14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p = 0.0015 for both), and serum HMW-adiponectin level increased from 2.07 ± 0.68 to 2.39 ± 0.99 μg/mL (+ 15.5%, p = 0.089). Conclusion: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.

KW - High-sensitivity C-reactive protein

KW - Insulin resistance

KW - Obesity

KW - PPAR gamma

UR - http://www.scopus.com/inward/record.url?scp=67549149196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549149196&partnerID=8YFLogxK

M3 - Article

C2 - 19403983

AN - SCOPUS:67549149196

VL - 16

SP - 137

EP - 142

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 2

ER -